• 中国核心期刊(遴选)数据库收录期刊
  • 中文科技期刊数据库收录期刊
  • 中国期刊全文数据库收录期刊
  • 中国学术期刊综合评价数据库统计源期刊等

中国药物评价 ›› 2020, Vol. 37 ›› Issue (4): 298-301.

• 药品评价 • 上一篇    下一篇

抗肿瘤药物的创新性评价研究

卢杉杉, 程希(男), 程希(女), 吴芙蓉, 张圣雨, 沈爱宗   

  1. 中国科学技术大学附属第一医院安徽省立医院药剂科, 安徽 合肥 230001
  • 收稿日期:2020-04-23 修回日期:2020-05-31 出版日期:2020-08-28 发布日期:2020-09-21

Analysis of Innovative Evaluation of Anti-tumor Drugs

  1. Department of Pharmacy, The First Affiliated Hospital of USTC Anhui Provincial Hospital, Anhui Hefei 230001, China
  • Received:2020-04-23 Revised:2020-05-31 Online:2020-08-28 Published:2020-09-21

摘要: 创新性评价是抗肿瘤药物综合评价的重要指标之一。本文通过检索国内外相关数据库,查阅药物评价相关研究文献,对抗肿瘤药物创新性评价的内容进行分析。探讨抗肿瘤药物的创新性的评价内容与实际意义,为拟定国家抗肿瘤药物政策,优化基本药物目录提供依据,同时为临床决策提供数据参考。
 

关键词: font-size:medium, ">药物评价;创新性评价;抗肿瘤药;评价指标

Abstract: Innovative evaluation is one of the important indicators of comprehensive evaluation of anti-tumor drugs. This article analyzes the content of innovative evaluation of anti-tumor drugs by searching relevant databases at home and abroad, consulting relevant research literature on drug evaluation. To explore the innovative evaluation content and practical significance of anti-tumor drugs, provide references for the formulation of national anti-tumor drug policies, optimize the list of essential drugs, and provide relevant basis for drug regulatory authorities and clinical decision-making.
 

Key words: font-size:medium, ">Drug evaluation; Innovative evaluation; Anti-tumor drug; Evaluation index

中图分类号: